NUTRALYS® Pea Protein Oral Supplementation Effects on Muscle Mass (nutralys)

April 29, 2014 updated by: Nicolas Babault

Controlled, Randomized, Parallel, Double-blind Study of the Effect of NUTRALYS® Pea Protein Supplementation Versus Whey Protein and Placebo on the Muscle Mass and Strength of Volunteers Engaged in Training

this clinical trial would try to confirm whether NUTRALYS®, a fast pea protein with an intermediate profile, rich in leucines and other essential amino acids, can significantly enhance muscle mass gain during strength training. This study will compare the efficacy of NUTRALYS® to a reference product. If the results of the study demonstrate a significant improvement in relation to the placebo, not inferior to that of whey, NUTRALYS® could be considered as an alternative to sports nutrition products, to which many people are intolerant.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Dijon, France, 21078
        • Centre d'Expertise de la Performance

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male subjects from 18 to 35 years of age:
  • engaged in moderate or occasional sports activity;
  • having given their written informed consent;
  • in gainful employment or a student;
  • in possession of a medical certificate of fitness for sports

Exclusion Criteria:

  • Subject already engaged in regular sports or training increasing muscle strength or volume in the upper limbs and particularly the biceps brachial;
  • Subject engaged or having engaged in the last 6 months in weight training more than once a week;
  • Subject having had a muscle injury in the 3 months prior to the study;
  • Asthmatic subject liable to be administered corticosteroids;
  • Subject taking part in another trial;
  • Subject with a known hypersensitivity to whey or pea proteins;
  • Subject deprived of their freedom for administrative, medical or legal reasons or not in possession of the legal or ethical capacity to enter into a contract due to cognitive function impairment;
  • Subject liable not to comply with the constraints required by the protocol;
  • Subject not covered by health insurance;
  • Subject having taken in the previous month or currently taking: medication, a dietary supplement, sports drink, food for particular nutritional uses or functional foods, of any kind, liable or described as liable to increase physical performance and notably to increase muscle mass;
  • Subject taking anabolic protein or corticosteroid treatment;
  • Subject on a high-protein diet.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo
Other Names:
  • Sachet for oral use composed of proteins (pea or whey) and/or other components (fat-reduced cocoa, flavouring, aspartame, salt, silica dioxide)
Active Comparator: whey protein
Other Names:
  • Sachet for oral use composed of proteins (pea or whey) and/or other components (fat-reduced cocoa, flavouring, aspartame, salt, silica dioxide)
Experimental: pea protein
Other Names:
  • Sachet for oral use composed of proteins (pea or whey) and/or other components (fat-reduced cocoa, flavouring, aspartame, salt, silica dioxide)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biceps brachial thickness measured using ultrasonography
Time Frame: 12 weeks after first ingestion
biceps muscle thickness measured in millimeter using images from ultrasonography
12 weeks after first ingestion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Elbow flexor strength
Time Frame: 12 weeks after first ingestion
Elbow flexors muscle strength measured in Newton meter using a Biodex isokinetic dynamometer in concentric, eccentric and isometric conditions.
12 weeks after first ingestion
Biceps circumference
Time Frame: 12 weeks after first ingestion
the circumference of the arm in three sites (proximal, middle and distal) using a tape (centimeter)
12 weeks after first ingestion
body weight
Time Frame: 12 weeks after first ingestion
Body mass in kg on a scale
12 weeks after first ingestion
tolerance
Time Frame: 12 weeks after first ingestion
Tolerance measured by quantifying adverse events
12 weeks after first ingestion
muscle force
Time Frame: 12 weeks after first ingestion
maximal weight lifted during an arm curl exercise (kg)
12 weeks after first ingestion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Francois A Allaert, MD, CEN Nutriment

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (Actual)

April 1, 2012

Study Completion (Actual)

August 1, 2012

Study Registration Dates

First Submitted

April 24, 2014

First Submitted That Met QC Criteria

April 29, 2014

First Posted (Estimate)

May 1, 2014

Study Record Updates

Last Update Posted (Estimate)

May 1, 2014

Last Update Submitted That Met QC Criteria

April 29, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • CEN1118

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on oral powder in sachet

3
Subscribe